[DNA damage checkpoint and cancer--pros and cons of Chk1 inhibitors]

[Article in Japanese]

Affiliations

Review

[Article in Japanese]

Hidemasa Goto et al. Seikagaku. 2013 Mar.

. 2013 Mar;85(3):145-51.

¹ Division of Biochemistry, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan.

No abstract available

Similar articles

Drug discovery targeting Chk1 and Chk2 kinases.
Zhou BB, Sausville EA. Zhou BB, et al. Prog Cell Cycle Res. 2003;5:413-21. Prog Cell Cycle Res. 2003. PMID: 14593735 Review.
Antagonism of Chk1 signaling in the G2 DNA damage checkpoint by dominant alleles of Cdr1.
Calonge TM, O'Connell MJ. Calonge TM, et al. Genetics. 2006 Sep;174(1):113-23. doi: 10.1534/genetics.106.060970. Epub 2006 Jul 2. Genetics. 2006. PMID: 16816416 Free PMC article.
Modulation of DNA damage checkpoint; patenting and possible application for cancer medicine.
Ishikawa K, Ishii H, Ichimura K. Ishikawa K, et al. Recent Pat DNA Gene Seq. 2008;2(1):34-9. doi: 10.2174/187221508783406512. Recent Pat DNA Gene Seq. 2008. PMID: 19075943 Review.
The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ, Fei HR, Cui YJ, Sun YK, Li ZM, Wang XY, Yang XY, Zhang JG, Sun BL. Wang FZ, et al. Apoptosis. 2014 Sep;19(9):1389-98. doi: 10.1007/s10495-014-1010-3. Apoptosis. 2014. PMID: 24928205
Checkpoint kinase inhibitors: a review of the patent literature.
Janetka JW, Ashwell S. Janetka JW, et al. Expert Opin Ther Pat. 2009 Feb;19(2):165-97. doi: 10.1517/13543770802653622. Expert Opin Ther Pat. 2009. PMID: 19441917 Review.

Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment.
Takahashi S. Takahashi S. Hematol Rep. 2023 May 24;15(2):331-346. doi: 10.3390/hematolrep15020035. Hematol Rep. 2023. PMID: 37367084 Free PMC article. Review.